ARGX.US.EQUI (ARGX.US.EQUI) News
Follow ARGX.US.EQUI (ARGX.US.EQUI) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 3 public stories across 3 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
argenx Strikes $2.2B Deal for Forte, Adds Autoimmune Drug FB102
argenx Strikes $2.2B Deal for Forte, Adds Autoimmune Drug FB102
EQUITY | Jul 27, 2026, 02:15 PM UTC
L
Argenx reports Q2 EPS $7.32, consensus $6.94
Reports Q2 revenue...
EQUITY | Jul 23, 2026, 01:09 PM UTC
H
Argenx price target raised to $945 from $890 at RBC Capital
RBC Capital raised the firm's price target on Argenx to $945 from $890 and keeps an Outperform rating on the shares as part of a broader research note previewing Q2 earnings in Biotech. The biotech sector has picked up c
EQUITY | Jul 07, 2026, 11:28 AM UTC